Ardelyx (ARDX) Competitors $4.33 +0.09 (+2.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.30 -0.03 (-0.58%) As of 08/1/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. AKRO, ACLX, ACAD, VKTX, SRRK, PTCT, SWTX, MLTX, PTGX, and AAPGShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), SpringWorks Therapeutics (SWTX), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Scholar Rock PTC Therapeutics SpringWorks Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International Ardelyx (NASDAQ:ARDX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Does the media refer more to ARDX or AKRO? In the previous week, Ardelyx had 2 more articles in the media than Akero Therapeutics. MarketBeat recorded 7 mentions for Ardelyx and 5 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 1.29 beat Ardelyx's score of 0.56 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ARDX or AKRO? Ardelyx has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Is ARDX or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.86%. Akero Therapeutics' return on equity of -15.19% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.86% -34.45% -13.81% Akero Therapeutics N/A -15.19%-13.97% Do analysts rate ARDX or AKRO? Ardelyx currently has a consensus target price of $10.88, suggesting a potential upside of 151.15%. Akero Therapeutics has a consensus target price of $82.50, suggesting a potential upside of 70.56%. Given Ardelyx's higher probable upside, equities research analysts clearly believe Ardelyx is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of ARDX or AKRO? 58.9% of Ardelyx shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, ARDX or AKRO? Ardelyx has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M3.11-$39.14M-$0.22-19.68Akero TherapeuticsN/AN/A-$252.06M-$1.95-24.81 SummaryArdelyx beats Akero Therapeutics on 11 of the 15 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-19.688.9728.6723.80Price / Sales3.11639.64422.2688.08Price / CashN/A157.7635.4557.96Price / Book5.934.838.275.55Net Income-$39.14M$31.62M$3.24B$259.03M7 Day Performance0.93%-5.28%-3.63%-4.56%1 Month Performance3.34%4.38%4.40%4.49%1 Year Performance-28.43%-2.49%25.97%18.05% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.1303 of 5 stars$4.33+2.1%$10.88+151.2%-21.3%$1.01B$333.61M-19.6890News CoverageUpcoming EarningsAKROAkero Therapeutics3.9446 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$4.03BN/A0.0030Positive NewsUpcoming EarningsACLXArcellx2.5739 of 5 stars$70.59-1.0%$111.23+57.6%+21.3%$3.93B$107.94M0.0080News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.988 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.89B$957.80M34.19510News CoverageUpcoming EarningsAnalyst RevisionVKTXViking Therapeutics3.7591 of 5 stars$33.20-3.5%$86.92+161.8%-40.2%$3.87BN/A0.0020Short Interest ↑SRRKScholar Rock3.7908 of 5 stars$37.09-4.8%$42.67+15.0%+301.3%$3.70B$33.19M0.00140News CoveragePositive NewsUpcoming EarningsAnalyst ForecastPTCTPTC Therapeutics4.482 of 5 stars$44.36-0.9%$65.77+48.3%+59.5%$3.55B$806.78M6.171,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionSWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsMLTXMoonLake Immunotherapeutics2.7013 of 5 stars$54.47-1.1%$73.14+34.3%+25.9%$3.53BN/A0.002News CoverageUpcoming EarningsPTGXProtagonist Therapeutics2.1351 of 5 stars$56.26+2.0%$66.10+17.5%+41.8%$3.42B$434.43M73.53120Positive NewsUpcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.30B$134.35M0.00600 Related Companies and Tools Related Companies AKRO Competitors ACLX Competitors ACAD Competitors VKTX Competitors SRRK Competitors PTCT Competitors SWTX Competitors MLTX Competitors PTGX Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
